Skip to main content

Advertisement

Featured Article: New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in clinical trials for bladder cancer patients that carry alterations in homologous DNA repair genes, letting to envisage susceptibility to the Poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors.

PARP inhibition, by amplifying the DNA damage, augments the mutational burden and promotes the immune priming of the tumor by increasing the neoantigen exposure and determining upregulation of programmed death ligand 1 (PD-L1) expression. Thus, the combination of PARP-inhibition and the PD/PD-L1 targeting may represent a compelling strategy to treat bladder cancer and has been introduced in recent clinical trials. The targeting of DDR has been also used in combination with epigenetic drugs able to modulate the expression of genes involved in DDR, and also able to act as immunomodulator agents suggesting their use in combination with immune-checkpoint inhibitors.

It may be envisaged the combination of three classes of drugs to treat bladder cancer, by targeting the DDR process in a tumor context of DDR defect, together with epigenetic agents and immune-checkpoint inhibitors, whose association may amplify the effects and reduce the doses and the toxicity of each single drug.

Click here to access the full article. 

Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

jeccreditorial@gmail.com​​​​​​​

Articles

Impact of COVID-19 on journal operations

COVID-19As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

We are trying our best to work through this crisis as efficiently and effectively as possible and thank you for your support and patience during these challenging times.

Thumbnail image by Felipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license.

Call for Papers: Hypoxia and Tumors

Hypoxia and Tumors © royaltystockphoto / FotoliaJournal of Experimental & Clinical Cancer Research is delighted to announce the launch of a new thematic series covering the hot topic of Hypoxia and Tumors.

The Special Issue will accept Research Articles and Reviews regarding the latest highlights on the role of hypoxia in all aspects of tumor progression, including therapy resistance and metastases. Submit here.

Submission opens: 1st December 2019
Submission deadline: 30th June 2020

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Celebrating the 10th anniversary partnership with BMC

JECCR 10 years​​​​​​​2018 marks the 10th anniversary of the partnership between the Journal of Experimental & Clinical Cancer Research and BMC.

Over the past decade, the journal has established itself among some of the top Oncology titles in Journal Citation Reports. Click here to look back at some of the journal’s milestone achievements and best content from the past 10 years.

Reviewer Acknowledgement and New Recruitment

© Syda Productions / fotolia.com




The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to jeccreditorial@gmail.com

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

jeccreditorial@gmail.com

Advertisement

Annual Journal Metrics

Advertisement